Higher haematocrit levels: do they improve patient outcomes, and are they cost effective?

被引：15

作者：

Collins, AJ ^{[1
]}

Keane, WF ^{[1
]}

机构：

[1] Univ Minnesota, Sch Med, Dept Med, Hennepin Cty Med Ctr, Minneapolis, MN 55455 USA

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 1998年 / 13卷 / 07期

关键词：

D O I：

10.1093/ndt/13.7.1627

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

引用

页码：1627 / 1629

页数：3

共 24 条

[1]

Barany P., 1996, Journal of the American Society of Nephrology, V7, P1472

[2] IMPROVED PHYSICAL PERFORMANCE AFTER TREATMENT OF RENAL ANEMIA WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN [J].

BRAUMANN, KM ;

NONNASTDANIEL, B ;

BONING, D ;

BOCKER, A ;

FREI, U .

NEPHRON, 1991, 58 (02) :129-134

[3]

COLLINS A, 1997, NEPHROLOGY S1, V3, pS187

[4]

Collins A, 1997, J AM SOC NEPHROL, V8, p190A

[5]

EKNOYAN G, 1997, CLIN PRACTICE GUIDEL

[6] THE ANEMIA OF CHRONIC RENAL-FAILURE - PATHO-PHYSIOLOGY AND THE EFFECTS OF RECOMBINANT ERYTHROPOIETIN [J].

ESCHBACH, JW ;

BOURDEAU, J ;

COE, F ;

TOBACK, G ;

COHEN, JJ ;

POCHEDLY, C ;

GARELLA, S ;

LAU, K ;

BUSHINSKY, D ;

SPRAGUE, S ;

KUMAR, S ;

SACKS, P ;

KATHPALIA, S ;

RICHTER, M ;

MADIAS, NE ;

HARRINGTON, JT .

KIDNEY INTERNATIONAL, 1989, 35 (01) :134-148

[7] CARDIOVASCULAR CONSEQUENCES OF CORRECTION OF THE ANEMIA OF RENAL-FAILURE WITH ERYTHROPOIETIN [J].

FELLNER, SK ;

LANG, RM ;

NEUMANN, A ;

KORCARZ, C ;

BOROW, KM .

KIDNEY INTERNATIONAL, 1993, 44 (06) :1309-1315

[8]

FISHBANE S, 1995, CLIN NEPHROL, V44, P238

[9] REDUCTION IN RECOMBINANT-HUMAN-ERYTHROPOIETIN DOSES BY THE USE OF CHRONIC INTRAVENOUS IRON SUPPLEMENTATION [J].

FISHBANE, S ;

FREI, GL ;

MAESAKA, J .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 26 (01) :41-46

[10] The safety of intravenous iron dextran in hemodialysis patients [J].

Fishbane, S ;

Ungureanu, VD ;

Maesaka, JK ;

Kaupke, CJ ;

Lim, V ;

Wish, J .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (04) :529-534

← 1 2 3 →